Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director
Trinity Biotech plc (Nasdaq: TRIB) has appointed David Ouston as Biosensor Marketing Director to drive growth for its innovative continuous glucose monitoring (CGM) technology. Ouston brings 16 years of experience in the glucose monitoring and diabetes health sectors, including roles at Johnson & Johnson and LifeScan. CEO John Gillard emphasized the importance of this strategic appointment for Trinity's long-term growth, particularly in rapidly expanding diabetes and wellness markets.
Ouston expressed enthusiasm for joining Trinity Biotech, highlighting the company's vision for an accessible and innovative CGM in global markets. He aims to leverage his extensive global leadership experience in promotion and market access strategies for diabetes management devices to help deliver Trinity's disruptive solution worldwide.
Trinity Biotech plc (Nasdaq: TRIB) ha nominato David Ouston come Direttore Marketing per i Biosensori per promuovere la crescita della sua innovativa tecnologia di monitoraggio continuo della glicemia (CGM). Ouston porta con sé 16 anni di esperienza nei settori del monitoraggio della glicemia e della salute diabetica, con ruoli presso Johnson & Johnson e LifeScan. Il CEO John Gillard ha sottolineato l'importanza di questa nomina strategica per la crescita a lungo termine di Trinity, in particolare nei mercati in rapida espansione della diabetologia e del benessere.
Ouston ha espresso entusiasmo per l'ingresso in Trinity Biotech, evidenziando la visione dell'azienda per un CGM accessibile e innovativo nei mercati globali. Il suo obiettivo è sfruttare la sua ampia esperienza di leadership globale nelle strategie di promozione e accesso al mercato per i dispositivi di gestione del diabete, al fine di contribuire a portare la soluzione innovativa di Trinity in tutto il mondo.
Trinity Biotech plc (Nasdaq: TRIB) ha nombrado a David Ouston como Director de Marketing de Biosensores para impulsar el crecimiento de su innovadora tecnología de monitoreo continuo de glucosa (CGM). Ouston aporta 16 años de experiencia en los sectores de monitoreo de glucosa y salud diabética, incluida su trayectoria en Johnson & Johnson y LifeScan. El CEO John Gillard enfatizó la importancia de este nombramiento estratégico para el crecimiento a largo plazo de Trinity, especialmente en los mercados de diabetes y bienestar que están en rápida expansión.
Ouston expresó su entusiasmo por unirse a Trinity Biotech, destacando la visión de la empresa sobre un CGM accesible e innovador en los mercados globales. Su objetivo es aprovechar su amplia experiencia en liderazgo global en estrategias de promoción y acceso al mercado para dispositivos de manejo de la diabetes, ayudando a llevar la solución disruptiva de Trinity a todo el mundo.
트리니티 바이오텍 plc (Nasdaq: TRIB)가 혁신적인 지속적 혈당 모니터링(CGM) 기술의 성장을 주도하기 위해 데이비드 아우스턴을 바이오센서 마케팅 디렉터로 임명했습니다. 아우스턴은 존슨앤존슨과 라이프스캔에서의 역할을 포함하여 혈당 모니터링 및 당뇨 건강 분야에서 16년의 경험을 가지고 있습니다. CEO 존 길라드는 트리니티의 장기 성장에 대한 이 전략적 임명의 중요성을 강조했으며, 특히 빠르게 성장하는 당뇨 및 웰빙 시장에서의 중요성을 강조했습니다.
아우스턴은 트리니티 바이오텍에 합류하게 되어 기쁘다고 하며, 세계 시장에서 접근 가능하고 혁신적인 CGM의 비전을 강조했습니다. 그는 당뇨 관리 장치에 대한 홍보 및 시장 접근 전략에 대한 광범위한 글로벌 리더십 경험을 활용하여 트리니티의 혁신적인 솔루션을 전 세계에 전달하는 데 기여할 계획입니다.
Trinity Biotech plc (Nasdaq: TRIB) a nommé David Ouston au poste de Directeur Marketing des Biosenseurs pour stimuler la croissance de sa technologie de surveillance continue du glucose (CGM) innovante. Ouston apporte 16 années d'expérience dans les secteurs de la surveillance du glucose et de la santé diabétique, ayant occupé des postes chez Johnson & Johnson et LifeScan. Le PDG John Gillard a souligné l'importance de cette nomination stratégique pour la croissance à long terme de Trinity, en particulier sur les marchés en pleine expansion du diabète et du bien-être.
Ouston a exprimé son enthousiasme à rejoindre Trinity Biotech, mettant en avant la vision de l'entreprise pour un CGM accessible et innovant sur les marchés mondiaux. Il a pour objectif de mettre à profit son vaste expérience en leadership mondial dans les stratégies de promotion et d'accès au marché pour les dispositifs de gestion du diabète, afin d'aider à déployer la solution perturbatrice de Trinity dans le monde entier.
Trinity Biotech plc (Nasdaq: TRIB) hat David Ouston zum Marketingdirektor für Biosensoren ernannt, um das Wachstum seiner innovativen Technologie zur kontinuierlichen Glukoseüberwachung (CGM) voranzutreiben. Ouston bringt 16 Jahre Erfahrung in den Bereichen Glukoseüberwachung und Diabetesgesundheit mit, unter anderem durch Tätigkeiten bei Johnson & Johnson und LifeScan. CEO John Gillard betonte die Bedeutung dieser strategischen Ernennung für das langfristige Wachstum von Trinity, insbesondere in den sich schnell entwickelnden Märkten für Diabetes und Wellness.
Ouston zeigte sich begeistert von seinem Eintritt in Trinity Biotech und hob die Vision des Unternehmens hervor, ein zugängliches und innovatives CGM auf den globalen Märkten anzubieten. Er beabsichtigt, seine umfassende globale Führungserfahrung in den Bereichen Promotion und Marktzugang für Diabetesmanagementgeräte zu nutzen, um die disruptive Lösung von Trinity weltweit zu verbreiten.
- Appointment of experienced Biosensor Marketing Director with 16 years in glucose monitoring sector
- Strategic focus on innovative, needle-free, reusable CGM technology as key growth driver
- Potential expansion into rapidly growing diabetes and wellness markets globally
- None.
DUBLIN, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the appointment of David Ouston as Biosensor Marketing Director. Mr. Ouston brings a wealth of commercial experience driving the growth of glucose monitoring devices at large, established companies across global markets.
John Gillard, President and Chief Executive Officer of Trinity Biotech, said, “We remain focused on our innovative, needle-free, reusable continuous glucose monitoring (CGM) technology as a key long-term growth driver for Trinity Biotech, and we are delighted to welcome David as a strategic appointment to our expanding team to help further this mission. His extensive global leadership experience in promotion and market access strategies for diabetes management devices and digital solutions will be a strong asset for Trinity Biotech as we prepare the roll out of our own CGM in rapidly growing diabetes and wellness markets.”
Commenting on his appointment, Mr. Ouston said, “I am thrilled to join Trinity Biotech to help realize its vision for an accessible and innovative CGM in global markets. Trinity’s device offers promising and exciting innovation in wearable biosensor technology and wellness analytics that can benefit more people globally to improve public health. I’m excited to work with this impressive team in delivering a truly disruptive and valuable solution to markets globally.”
Mr. Ouston’s career spans 16 years in the glucose monitoring and diabetes health sectors, including global and EMEA regional marketing roles at Johnson & Johnson and LifeScan, where he led innovations in the OneTouch glucose monitoring portfolio. Previously, he held marketing positions at private healthcare provider Bupa, where he supported the promotion of their global healthcare brand. Mr. Ouston holds a Bachelor of Arts Degree in Business Administration from Brunel University in the U.K.
Forward-Looking Statements
This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterised by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on our purchase of the assets of Waveform, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, the impact of the spread of COVID-19 and its variants, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2023 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.
About Trinity Biotech
Trinity Biotech is a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.
| Contact: | Trinity Biotech plc | LifeSci Partners, LLC |
| Gary Keating | Eric Ribner | |
| (353)-1-2769800 | (1)-646-751-4363 | |
| investorrelations@trinitybiotech.com | ||
| RedChip Companies Inc. | ||
| Dave Gentry, CEO | ||
| (1)-407-644-4256 | ||
| TRIB@redchip.com |
FAQ
Who is David Ouston and what is his new role at Trinity Biotech (TRIB)?
What is Trinity Biotech's (TRIB) focus in the diabetes management market?
How might David Ouston's appointment impact Trinity Biotech's (TRIB) market strategy?
What are the potential benefits of Trinity Biotech's (TRIB) CGM technology?
